Milestone Pharmaceuticals (MIST) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free MIST Stock Alerts $1.72 +0.02 (+1.18%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 2:15 AM | morningstar.comMilestone Pharmaceuticals Inc MISTMay 13 at 4:12 PM | washingtonpost.comMilestone Pharmaceuticals: Q1 Earnings SnapshotMay 13 at 7:15 AM | globenewswire.comMilestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateMay 2, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024April 28, 2024 | marketbeat.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Decreases By 22.9%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 431,400 shares, a decline of 22.9% from the March 31st total of 559,500 shares. Based on an average daily volume of 312,600 shares, the short-interest ratio is currently 1.4 days.April 17, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 17, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 13, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8%Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8%April 8, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 8, 2024 | globenewswire.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceApril 1, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual ConferencesMarch 28, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular TachycardiaMarch 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)March 22, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Friday.March 21, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy RecommendationMarch 21, 2024 | investorplace.comMIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023March 21, 2024 | globenewswire.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate UpdateMarch 5, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Price Target Lowered to $5.00 at Piper SandlerPiper Sandler lowered their target price on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday.February 29, 2024 | globenewswire.comMilestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsFebruary 28, 2024 | marketwatch.comMilestone Pharma Shares Drop After Public Offering NewsFebruary 28, 2024 | msn.comMilestone Pharmaceuticals launches stock and warrants offeringFebruary 28, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsFebruary 26, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial OutlookFebruary 26, 2024 | msn.comWhy Milestone Pharmaceuticals (MIST) Stock Is RisingFebruary 26, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVTFebruary 21, 2024 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST) Insider TradesFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA ApprovalFebruary 11, 2024 | finance.yahoo.comMilestone Pharmaceuticals Inc. (MIST)January 31, 2024 | reuters.comNovartis eyes 5% annual sales growth through 2028January 30, 2024 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest UpdateMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 405,600 shares, a decline of 14.9% from the December 31st total of 476,800 shares. Based on an average daily volume of 270,100 shares, the short-interest ratio is presently 1.5 days.January 25, 2024 | businesswire.comDr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist TechnologyJanuary 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MISTJanuary 16, 2024 | finance.yahoo.comDown -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a TurnaroundDecember 30, 2023 | markets.businessinsider.comROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MISTDecember 28, 2023 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST), Analyst Ratings, Price Targets, PredictionsDecember 28, 2023 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST) Dividends: History, Yield and DatesDecember 27, 2023 | markets.businessinsider.comMilestone Pharmaceuticals Earns Buy Rating Amid Promising Clinical Trials and Market PotentialDecember 27, 2023 | finance.yahoo.comMilestone Pharma (MIST) Down on Regulatory Update for EtripamilDecember 26, 2023 | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MISTDecember 26, 2023 | markets.businessinsider.comMilestone Pharma Receives Refusal To File Letter From FDA For NDA For Etripamil In PSVT TreatmentDecember 26, 2023 | msn.comWhy Is Heart Disease-Focused Milestone Pharmaceuticals Stock Plummeting Today?December 26, 2023 | finance.yahoo.comMilestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutionsDecember 26, 2023 | finance.yahoo.comMilestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVTDecember 26, 2023 | marketbeat.comTrading was temporarily halted for "MIST" at 06:12 AM with a stated reason of "News pending."November 21, 2023 | finance.yahoo.comMilestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 17, 2023 | morningstar.comU.S. Economic Outlook 2023: GDP and Interest-Rate ForecastsNovember 15, 2023 | finance.yahoo.comMilestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022)November 13, 2023 | finance.yahoo.comMilestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. MIST Media Mentions By Week MIST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼0.970.57▲Average Medical News Sentiment MIST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼51▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANIX News PRPH News ONCY News ACRS News SPRO News ETON News CLSD News CMRX News BRNS News ORMP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
